Navigation Links
The Cambridge Group Names Two New Principals
Date:10/16/2007

CHICAGO, Oct. 16 /PRNewswire/ -- The Cambridge Group, a leading strategy consulting firm, today named Mark Miller and Carrie Shea principals of the firm.

Mr. Miller brings more than 20 years of management consulting and industry experience to The Cambridge Group. In his career, Mr. Miller focused on driving strategic and operational improvements in senior executive and consulting positions. In his most recent role as a principal at Archstone Consulting, he was responsible for the launch and development of the firm's Central Region.

Prior to joining Archstone Consulting, Mr. Miller served as vice president of organizational effectiveness for Motorola, Inc.'s Mobile Device business and as chief operating officer of Entrade, Inc., a NYSE-listed internet software company. As vice president and practice leader at A.T. Kearney, Inc., where he spent nearly 13 years, Mr. Miller consulted on business and marketing strategy issues across multiple industries. He is a board member of the National Chamber Foundation of the US Chamber of Commerce and serves on the Chicago Make-A-Wish fundraising committee.

Mr. Miller earned an MBA from Harvard Business School as well as a BBA and BS from Southern Methodist University.

Ms. Shea also brings more than 20 years of management consulting and industry experience to The Cambridge Group. Most recently as a principal and practice leader at Archstone Consulting, Ms. Shea led the firm's Global Strategy Practice. Prior to Archstone Consulting, she worked at A.T. Kearney as a vice president in the Strategy and Consumer Products Practices. Ms. Shea also held management positions at Entrade, Inc., Johnson & Johnson Baby Products and Lexecon, Inc., an economic consulting firm. Ms. Shea serves on the boards of the Joffrey Ballet, the Chicago Chapter of the American Cancer Society and the Lake Forest Open Lands Association.

Ms. Shea earned an MBA and BA from the University of Chicago.

"We are very pleased
'/>"/>

SOURCE The Cambridge Group
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. No link between blood groups and prostate cancer
2. Consumer group seeks Sibutramine ban
3. Suicide risk high in 12-17 Age Group
4. Religious groups overcome objections to cervical cancer vaccines
5. Wockhardt Group Plans Hospital In Delhi By End-2007
6. Group Suicides On The Rise In Japan
7. Yogic Moments: Age Old Yoga, Benefits All Age Groups
8. Group Jogging More Beneficial To Health Than Solo Jogging
9. Plastic Surgery Is Primetime among Ethnic Groups
10. Study Finds Online Support Groups Emotionally Benefit Women Suffering From
11. Specialist Services Can Help Ethnic Groups To Tackle Alcohol Misuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2008)...f a partial blockage last fall , , SATUR... Edward M. Kennedy was taken from a local hospital...assachusetts General Hospital in Boston early Satu...d possibly a second one, according to news reports... hospital, according to an early afternoon news re...
(Date:5/17/2008)...ather to tell motorists ,Click It or Ticket ...hoolers display art and videos promoting seat belt...t: Local kickoff of the 2008 "Click It or Ticket... Monday, May 19, 2008 Noon (free buffet l...here: The Cleveland House of Blues 308 E...
(Date:5/16/2008)...ire/ -- In the aftermath of central China,s,earthq... their lives, and,over 150,000 were injured. An es... 4 million who have lost their homes. With great s...upreme Master Ching Hai donated an,additional US$3...s from,Supreme Master Ching Hai International Asso...
(Date:5/16/2008)NEW YORK, May 16 /PRNewswire/ -- There,s more to a healthy mouth than,flashing a set of pearly whites. Here,s the scoop on America,s oral care,habits - and what it means for our overall health.,
Breaking Medicine News(10 mins):Health News:Sen. Edward Kennedy Hospitalized After Seizure 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 2Health News:Northeast Ohio Kicks Off the 2008 Click It or Ticket Campaign 3Health News:Supreme Master Ching Hai International Association Delivering US$160,000 in Aid to Earthquake Survivors in China 2
... Christopher Moir at Minnesota's Mayo Clinic has s...ns from Bismarck, North Dakota// (ND) and now they...r chest walls. Abygail and Madysen Fitterer, the ...uzy Fitterer and who were born joined at the chest...
...on's appear to increase the risk of heart valve di...a degenerative disorder of the central nervous sys...eart valves are one-way valves that keep blood flo... through the heart. If people have problems with t...
...nce that suggests a link between a particular gene...x infection//. The journal, Neurobiology of Aging,...individuals, the same gene is implicated in causin... is of much interest to the scientific world. It r...
...s received tentative approval from the US Food and...rtraline Hydrochloride for// treatment of major de... Hydrochloride tablets will be the AB-rated generi...loft tablets of 25mg, 50mg and 100mg dosage. "Th...
Other Medicine News:Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 2Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 3Health News:Herpes Simplex and Alzheimer’s Disease Linked to Single Gen 4
(Date:5/16/2008)...at ASCO Annual Meeting Will Further Demonstrate, ...e Multiple Myeloma -, CAMBRIDGE, Mass., May 16 /P...da Oncology Company, today announced that new data... featured at the 2008 American Society,of Clinical...is, May 30 -,June 3, 2008. The data will highlight...
(Date:5/16/2008)... industry and customer thought leaders -, SAN FRA...cognized,leader and trusted resource for clinical ...llation of prestigious academic medical centers, r...annual user group meeting in San,Francisco. The Ve...y and,collaboratively manage thousands of clinical...
(Date:5/16/2008)...- Results demonstrating that TYKERB and trastuzuma...ension of progression-free survival (PFS), -- Com...nside and,outside of the HER2 receptor may create ...ing activity of TYKERB alone despite patients,pre... and chemotherapy, LONDON and PHILADELPHIA, May 1...
(Date:5/16/2008)...- Veridex, LLC announced today that,i...of America Holdings,(LabCorp), has commercially la...ncer. The new assay uses the biological specificit...ng the methylation of the gene,GST-Pi. Methylation...,cancer. Veridex is developing the methylation mar...
Breaking Medicine Technology:New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 1Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 2Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 3Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 4Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 5Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 6Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 7Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 8Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 9Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 10Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 11Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 12Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 13Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 14Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 15Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 16Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 17Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 18Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 19Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 20Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 21Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 22Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 23Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 24Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 25Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 26Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 27Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 28Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 29Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 30Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 31Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 32Shire plc 3A Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36 25 3442 33Dr Mark Nestor Presents on Pyratine 6 28TM 29 at the South Beach Symposium 3440 1Dr Mark Nestor Presents on Pyratine 6 28TM 29 at the South Beach Symposium 3440 2Dr Mark Nestor Presents on Pyratine 6 28TM 29 at the South Beach Symposium 3440 3Accumetrics Announces 2428 8 Million Financing and Initiation of Pivotal Clinical Trial 1406 1Accumetrics Announces 2428 8 Million Financing and Initiation of Pivotal Clinical Trial 1406 2Cancer Cure Coalition Proposes Major Changes at the FDA 1404 1Cancer Cure Coalition Proposes Major Changes at the FDA 1404 2Cancer Cure Coalition Proposes Major Changes at the FDA 1404 3
... 2007 /PRNewswire-FirstCall/ -- Boston,Scientific ...rticle,in the Journal of of Cardiology (JACC) revi...tes the Company,s second-generation,TAXUS(R) Liber...icle in the April 24 edition of JACC concluded tha...e of the TAXUS Liberte Stent,system compared to th...
...--Jun 4, 2007 - Pfizer announced today that,axitin... inhibitor,of VEGFR 1, 2,3 (vascular endothelial g...itabine showed a trend towards prolonged,overall s...cancer,compared with gemcitabine alone, according...ial., These data were presented at the 43rd Americ...
Other Medicine Technology:Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 2Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 3Positive Results for Second-Generation Taxus Liberte Coronary Stent,System Highlighted in Journal of American College of Cardiology 4New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 2New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 3New Data Show Pfizer's Axitinib Prolonged Overall Survival in,Advanced Pancreatic Cancer When Combined with Standard of Care,Chemotherapy 4
...sthesia and Respiratory Products, ,Westmed design...al devices for Anesthesia and Respiratory professi...oducts that enhance the clinician's ability to del...tion to the bottom line. , ,Our web site is desig...
...sthesia and Respiratory Products, ,Westmed design...al devices for Anesthesia and Respiratory professi...oducts that enhance the clinician's ability to del...tion to the bottom line. , ,Our web site is desig...
... medication nebulizer achieves optimum lung penetr...MMAD particle size range is 1.04-1.10 µ at 6...sor or air outlet., ,As the world leader in airwa...oviders the assurance of proven technology by offe...
... medication nebulizer achieves optimum lung penetr...MMAD particle size range is 1.04-1.10 µ at 6...sor or air outlet., ,As the world leader in airwa...oviders the assurance of proven technology by offe...
Medicine Products: